The 7th International Investigative Dermatology Meeting (IID 2018) has expanded and developed over recent years and is now a high profile event which draws a diverse group of senior researchers and clinicians, as well as hundreds of clinical trainees including Dermatology residents from around the world. IID 2013 saw over 2,400 delegates in attendance. We anticipate over 2,700 attendees for IID 2018.
IID 2018 will provide you with a unique platform to meet with partner scientists, clinical investigators and clinicians, and also the ability to forge new cooperation with key opinion leaders, clinical or laboratory scientists, educators and allied health professionals.
Space is limited, reserve your booth today!
Exhibits will be staffed during the following times in Gatlin A-C
Thursday, May 17, 2018 11:45 am – 1:45 pm
Friday, May 18, 2018 12:00 pm – 2:00 pm
Saturday, May 19, 2018 11:45 am – 1:45 pm
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.
BioIVT, formerly BioreclamationIVT, is a leading provider of control and disease state samples (human/animal tissues, cells, blood, biofluids). Our PHASEZERO team provides value-added services that evaluate the efficacy and safety of therapeutics. Combining technical expertise, exceptional customer service, and unparalleled access to biospecimens, BioIVT partners with scientists in ELEVATING SCIENCE.
CYTOO is a Contract Research Organization developing more physiological cell-based assays fully compatible with High-Content Screening and High-Content Analysis.
FibroTx brings personalized treatment closer to the customer in areas of clinical dermatology and skin care. FibroTx easy to use skin molecular diagnostic tests allow unparalleled possibilities for non-invasive skin biomarker research and product development in clinical dermatology and skin care.
Genoskin Inc. is a biotechnology company based in Boston (MA) and Toulouse (France) that provides unique standardized and ready-to-use ex vivo human skin models to predict efficacy and toxicity of chemical, pharmaceutical and cosmetic products, as well as medical devices, as an alternative to animal experiments. Our cutting-edge technology enables the evaluation of topical and systemic administration, subcutaneous injection and anti-Th1/Th17 inflammatory drugs. We also provide tools for tissue culture as well as in-house R&D services. The company is ISO9001:2015 certified.
Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Over the decades, we have established ourselves as a leading player in the discovery of new molecules both NCEs (New Chemical Entity) and NBEs (New Biological Entity). We have several molecules in various stages of pre-clinical and clinical development and are primarily focused in the areas of Oncology, Respiratory and Dermatology.
gpskin is a skin measurement and management service that provides users with important information about their skin so optimum care can be possible
ImaBiotech supports pharmaceutical industry with innovative Imaging services that predict more accurately which treatment will work in stratified population. ImaBiotech is a Contract Research Organization (CRO) with two facilities one in Boston (MA) and one in France. The company offers innovative services to the pharmaceutical research to provide better drug efficacy and toxicity evaluations from preclinical to clinical stages, making better and safer drugs. Services are based on different imaging techniques combined to Quantitative Mass Spectrometry a technology developed and constantly improved by ImaBiotech. Quantitative Mass Spectrometry (QMSI) has been developed for decades and allows to detect elements and molecules without labelling. ImaBiotech has developed the quantitative aspects through many patents making ImaBiotech the worldwide leader in this field. QMSI is a game changer of the pharmaceutical industry in all therapeutic areas. While actual techniques provide global information, this molecular technique brings deeper information about drug localization and its pharmacology effects to recover disease tissues and damaged cells. This increases the interpretation of drug efficacy and toxicity improving drugs and improving time to market. To interpret datas we’ve developed, thanks to our patents, two softwares called Quantinetix and Multimaging to interpret pharmacology in tissue.
As a Clinical Research Organization specialized in Dermatology, we provide scientific guidance, accurate results and customer satisfaction. Our unique service offering combines specialized Contract Research Services, knowledge of dermatology sites in North America and the extended capabilities of a large clinical research site.
Founded in 2004, the International Psoriasis Council (IPC) is a dermatology-led, voluntary, global nonprofit organization dedicated to innovation across the full spectrum of psoriasis through research, education and patient care. With more than one hundred board members and councilors from twenty-nine countries, IPC embodies the global expertise of multi-specialty psoriasis key opinion leaders. These leaders include representatives from dermatology, basic science, translational research, genetics, epidemiology, cardiology, psychology, international clinical trials, and direct patient care.
We were founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: “Take what you find here and make it better and better.”
More than 140 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live.
Mary Kay Inc. is one of the top innovators in the direct selling and skin care industries. With more than 1400 patents for products, technologies, and packaging designs in its global portfolio, Mary Kay Inc. continuously develops new technology and innovative products. Mary Kay invests heavily in the research and development of new technologies that can evaluate the safety and efficacy of our products, and we collaborate with experts in the scientific and academic fields to advance the science of safety testing.
Mary Kay Inc. continues its commitment to the advancement of skin science research by sponsoring the symposium on “Pollution and Skin Health” at the International Investigative Dermatology conference.
MatTek Corporation was founded in 1985 by two chemical engineering professors from MIT. In 1991 the company leveraged its core polymer surface modification technology into the emerging tissue engineering market.
MatTek Corporation is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models. Our skin, ocular, and respiratory tissue models are used in regulatory toxicology (OECD, EU guidelines) and address toxicology and efficacy concerns throughout the cosmetics, chemical, pharmaceutical and household product industries.
Metabolon, Inc. is the world’s leading health technology company advancing metabolomics in precision medicine and life sciences research. Its Precision Metabolomics™ is a powerful technology for assessing health and delivering biomarker discoveries, innovative diagnostic tests, and valuable data for genomics and population health initiatives.
The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases.
Perimed provides instruments, software and expertise to enable assessment of the microcirculation. They utilize laser Doopler, laser speckle (LASCA) and transcutaneous oximetry (tcpO2 or TCOM) to accuratley monitor and quantify blood perfusion and tissue oxygenation in real-time. Their PeriCam PSI Imagers have been used to measure microcirculatory blood flow in a wide range of applications.
Preclinical Medevice Innovations (PMI) is a leader in preclinical medical device contract research with over 25 years of experience in experimental surgery. With four surgical suites and imaging equipment including a Cath lab, c-arms, ultrasound, endo and lap towers, PMI is fully equipped to handle all of your study needs from research and development to non-GLP and GLP. We take a collaborative approach with our clients understanding the complexities of research and the unique needs of individual companies. Our longevity coupled with our expertise will help you get your device to the market more effectively and efficiently than any other preclinical medical device CRO.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Sanofi, a global healthcare leader, discovers, develops, & distributes therapeutic solutions focused on patients’ needs. Since 2007, Sanofi & Regeneron have collaborated to develop & commercialize fully human monoclonal antibodies utilizing proprietary technologies.
Sinclair Research offers specialized biomedical research in a range of species, covering most categories of applied human and veterinary medicine. Our uniqueness includes our broad experience spanning more than 20 years, availability of multiple preclinical animal models, and the largest herds of miniature swine in the United States. We remain flexible and can tailor our efforts to nearly any special procedures that are requested or designed. We strive to attract and retain our clients through competitive pricing, strong communication, timeliness and responsive preclinical research services.
Syntimmune is a clinical-stage biopharmaceutical company developing a range of drug candidates. Our lead molecule, SYNT001, which is advancing into multicenter US trials in pemphigus and warm autoimmune hemolytic anemia, targets the interaction between FcRn and IgG, modulating IgG levels as well as IgG-related inflammation and their roles in a wide range of autoimmune diseases.
Tergus is a full-service CRO for topical pharmaceutical research & development, testing and cGMP manufacturing in a state-of-the-art facility in Durham, NC. From deep expertise in formulation development of topical formulations, and knowledge of the regulatory landscape to the unique capability of Proof of Concept (PoC) studies such as Skin Permeation / In Vitro Permeation Test (IVPT), In Vitro Release Test (IVRT), and Clinical Supplies Manufacturing (Phase I, II and III Batches), Tergus act like an like an extension to the laboratory to help companies get to market faster.
Zen-Bio is a leading global provider of advanced cell-based solutions and services to the life science, cosmetics, and personal care communities. The company, founded in 1995, was a pioneer in adipose derived stem cells (ASCs) and continues this legacy by providing cutting edge human primary cell culture products and services. Our mission is to provide the highest quality human cell systems, reagents, blood products and contract services to our research partners; to develop and commercialize innovative research tools, leverage our expertise through research and development and strategic alliances that accelerate discovery.